ClinicalTrials.gov
public full text
Public Domain
Rituximab, Cyclophosphamide, and Corticosteroids in Primary Membranous Nephropathy
This exploratory study aims to assess the efficacy, safety of the experimental treatment based on a combination of rituximab (RTX), intravenous (IV) cyclophosphamide (CYC), and corticosteroids (S) administrated at lower cumulative doses (RCP) for the induction of early remission in subjects with anti-PLA2R antibody-positive primary membranous nephropathy (PMN) having nephrotic syndrome (NS).
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Clinical Study of Rituximab for the Treatment for Idiopathic Membranous Nephropathy With Nephrotic Syndrome#1100980
- The personalized approach to rituximab treatment in membranous nephropathy: a multi-center randomized controlled trial#311909
- Rituximab in the First Episode of Paediatric Nephrotic Syndrome#848148
- MEmbranous Nephropathy Trial Of Rituximab#882694
- Efficacy and Safety of Rituximab Therapy to Sustain Remission in Young Children With Childhood Nephrotic Syndrome#262012
Record · ID 837484
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive